Aleris Due Diligence
Run due diligence on Aleris: check compliance and get alerts when suppliers change.
Sweden · aleris.se · 11 vendors
Aleris is a Scandinavian healthcare provider focused on specialist medical care. The company operates clinics throughout Sweden from Malmö in the south to Umeå in the north, serving thousands of patients daily with specialized medical services.
Resilience scores
- Digital Sovereignty: 27
- Digital Resilience: 7
- Financial Resilience: 7
Technology vendors
- Apple Inc. — Technology — United States
- OpenAI — Technology — United States
- Tandem Health — Sweden
- and 8 more
Services catalogue
3 services in catalogue across 1 category; runs on 11 sub-vendors.
- Logistics Management
- Optimization Software
- Terminal Operating System
Insights
Last updated 2026-08-16 · revision 2
11 direct vendors, 170 subvendors
Direct vendors by controlling owner country (sample)
- Finland: 1
- United States: 7
- Sweden: 1
Subvendors by controlling owner country (sample)
- Poland: 1
- Australia: 3
- France: 7
Compliance
9 in-scope frameworks identified; showing 3.
MDR — No public evidence
Evidence: https://www.aleris.se/plastikkirurgi/, https://www.aleris.se/ogon/linsbyte/, https://www.aleris.se/ortopedi/privat/, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745, https://www.lakemedelsverket.se/
CSRD (source) — No public evidence
Evidence: https://unglobalcompact.org/what-is-gc/participants/25111-Aleris-, https://www.aleris.se/om-aleris/kvalitet-hallbarhet/, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022L2464
Patientsäkerhetslagen — No public evidence
Evidence: https://cms.aleris.se/siteassets/om-aleris/aleris_kvalitetsrapport_2024.pdf, https://www.aleris.se/om-aleris/, https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/patientsakerhetslag-2010659_sfs-2010-659/, https://www.ivo.se/
Financials
Three-year financials
- 2025:
- 2024:
- 2023:
Financial Resilience Score: 7/10
Aleris demonstrates solid financial resilience underpinned by its scale as a leading Scandinavian private specialist healthcare provider operating across Sweden, Norway, and Denmark. The group benefits from significant geographic diversification across three Nordic markets, a diversified payer mix (public healthcare contracts, private health insurance, and self-pay), and a broad service portfolio spanning orthopaedics, ophthalmology, psychiatry, primary care, diagnostics, and plastic surgery. Management described FY2024 as a year of 'record growth,' and FY2025 saw patient visits reach approximately 3.8 million, up ~7% YoY, indicating strong operational momentum. The group is backed by Triton Partners, a well-capitalised private equity owner that has funded bolt-on M&A (CT-klinikken in Denmark, Nordiskt Centrum in Linköping) and major capex projects including a new Malmö hospital with Hemsö targeted for 2027. The pending 2025 sale to Finnish healthcare provider Mehiläinen further validates enterprise value and would provide a credible industrial owner post-transaction. However, resilience is tempered by exposure to regulatory and political risk in Nordic private healthcare (particularly the Swedish 'vinster i välfärden' debate), tender concentration in public procurement, ongoing wage inflation and clinical staff shortages, and capex intensity. As a PE-owned group, Aleris likely carries meaningful leverage, though precise figures were not extracted. Deal-closing risk on the Mehiläinen transaction remains pending regulatory approval. Overall, the combination of scale, diversification, and strong owner backing supports an above-average resilience score.
Key strengths: Scale and geographic diversification across Sweden, Norway, and Denmark, Diversified payer mix: public healthcare, private insurance, and self-pay, Broad service portfolio across multiple specialties, Strong Nordic private-health tailwind from public waiting lists and ageing populations, Backing from well-capitalised PE owner Triton Partners, Pending acquisition by Mehiläinen validates enterprise value, Record growth in FY2024 and ~7% YoY patient visit growth in FY2025, Aleris Elisabethsjukhuset ranked Sweden's best hospital 2025
Risk factors: Regulatory/political risk on for-profit healthcare in Nordic countries, Tender concentration and repricing risk in public procurement contracts, Wage inflation and clinical staff shortages across the Nordics, Capex intensity for hospitals and imaging equipment (e.g., Malmö hospital 2027), Likely meaningful leverage as PE-owned group, Deal-closing risk on pending Mehiläinen acquisition
Workforce by country
- Total (Scandinavia): 5800
Signed-in users can see whether their own company is exposed to this vendor's disruption, plus the full sub-vendor list and country breakdowns, every in-scope compliance framework plus gaps and next steps, and alerts when any of it changes.